Sunesis and MMRC collaborate to study SNS-032 in myeloma
Sunesis and MMRC collaborate to study SNS-032 in myeloma
SOUTH SAN FRANCISCO, California-Sunesis Pharmaceuticals, Inc. and the Multiple Myeloma Research Consortium (MMRC) have entered into a collaboration to evaluate Sunesis' SNS-032 for the treatment of multiple myeloma. SNS-032 is a potent, selective inhibitor of cyclin-dependent kinases (CDKs) 2, 7, and 9 that inhibits both cell cycle progression and transcription.
Articles in this issue
New tobacco product alert: Camel Snus is on the loose
Blueberry punch not quite a 'knock out' blow
Texas voters listen to Lance
Cellectar opens manufacturing facility for radiolabeled CLR1404
High cost of breast MRI screening appears to be justified
Broccoli Sprouts Extract Might Lower Bladder Cancer Risk
Xeloda/Ixempra Effective in Resistant Triple-Negative Ca
Steven Rosen, MD, accepts Editor-in-Chief position for Oncology News International
Statins during RT may lower risk of prostate ca relapse
Call for congressional hearing on Provenge approval process re-ignites FDA conflict-of-interest controversy
Major policy issue lies behind ODAC's Avastin decision
Zevalin boosts PFS in advanced follicular NHL patients
Breast MRI reveals occult cancers in PBI candidates
Researchers defend NLST protocol against its critics
High-dose neoadjuvant fulvestrant tested
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
Related Content
